Literature DB >> 7439636

Liver in the cerebro-hepato-renal syndrome: defective bile acid synthesis and abnormal mitochondria.

R K Mathis, J B Watkins, P Szczepanik-Van Leeuwen, I T Lott.   

Abstract

Two infants with the cerebro-hepato-renal syndrome (Zellweger's disease) exhibited cholestasis and progressive liver damage. Because abnormalities of mitochondrial structure and function have been reported in this condition, we examined the bile acids for evidence of defects in the mitochondrial phase of bile acid synthesis, namely, oxidation of the cholesterol side chain to form C-24 bile acids. The presence of increased amounts of the C-27 bile acid intermediates (trihydroxycoprostanic acid, varanic acid, and dihydroxycoprostanic acid) were noted and identified by gas-liquid chromatography-mass spectrosocopy confirming that a defect in the mitochondrial pathways for bile acid side chain cleavage is involved in this entity. The clinical course, liver histopathology, and hepatocyte ultrastructural abnormalities suggest that these bile acids may reflect an underlying mitochondrial dysfunction in this disease and possibly may contribute to the progressive hepatic lobular fibrosis observed in these patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439636

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Carbohydrate metabolism is perturbed in peroxisome-deficient hepatocytes due to mitochondrial dysfunction, AMP-activated protein kinase (AMPK) activation, and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) suppression.

Authors:  Annelies Peeters; Peter Fraisl; Sjoerd van den Berg; Emiel Ver Loren van Themaat; Antoine Van Kampen; Mark H Rider; Hiroshi Takemori; Ko Willems van Dijk; Paul P Van Veldhoven; Peter Carmeliet; Myriam Baes
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

2.  Pathology of hepatic peroxisomes and mitochondria in patients with peroxisomal disorders.

Authors:  J L Hughes; A Poulos; E Robertson; C W Chow; L J Sheffield; J Christodoulou; R F Carter
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 3.  On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders.

Authors:  J P Infante; V A Huszagh
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

4.  Defective peroxisomal cleavage of the C27-steroid side chain in the cerebro-hepato-renal syndrome of Zellweger.

Authors:  B F Kase; I Björkhem; P Hågå; J I Pedersen
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 5.  Bile acids: the role of peroxisomes.

Authors:  Sacha Ferdinandusse; Simone Denis; Phyllis L Faust; Ronald J A Wanders
Journal:  J Lipid Res       Date:  2009-04-08       Impact factor: 5.922

Review 6.  Teratogenic inborn errors of metabolism.

Authors:  J V Leonard
Journal:  Postgrad Med J       Date:  1986-02       Impact factor: 2.401

Review 7.  Liver pathology and immunocytochemistry in congenital peroxisomal diseases: a review.

Authors:  F Roels; M Espeel; D De Craemer
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

8.  Platelet-activating factor: mediator of the third pathway of platelet aggregation? A study in three patients with deficient platelet-activating factor synthesis.

Authors:  A Sturk; M C Schaap; J W ten Cate; H S Heymans; R B Schutgens; H Przyrembel; P Borst
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

Review 9.  Very long chain fatty acids in higher animals--a review.

Authors:  A Poulos
Journal:  Lipids       Date:  1995-01       Impact factor: 1.880

10.  Peroxisomal beta-oxidation enzyme proteins in adrenoleukodystrophy: distinction between X-linked adrenoleukodystrophy and neonatal adrenoleukodystrophy.

Authors:  W W Chen; P A Watkins; T Osumi; T Hashimoto; H W Moser
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.